Grail (GRAL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$165.3M

Revenue (quarter)

$44.7M

Revenue growth (year over year)

+25.72%

Gross profit (trailing twelve months)

−$51.7M

Gross margin

−31.31%

Net income (trailing twelve months)

−$391.6M

Net income (quarter)

−$110.2M

Net income growth (year over year)

+3.28%

Net margin

−236.95%

Return on equity

−16.12%

EPS (trailing twelve months)

−$9.69

Book value per share

$56.93

P/E (trailing twelve months)

—

Price to book

2.45

Debt to assets

10.59%

Payout ratio

—

Dividend yield

—

Company profile

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

• Is Grail (GRAL) profitable?

  No. Grail reported a net loss of $391.6M over the trailing twelve months.

• How much revenue does Grail (GRAL) make?

  Grail generated $165.3M in revenue over the trailing twelve months, up 25.72% year over year.

• How do I buy stock in Grail (GRAL)?

  GRAL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.